Rahul Singhvi, ScD, MBA, is Chief Operating Officer of Takeda’s Global Vaccine Business Unit and is responsible for global supply of vaccines at the Takeda Pharmaceutical Company.
Dr. Singhvi is a recognized business leader in the pharmaceutical industry and has deep experience in vaccine development and manufacturing. Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, a Nasdaq-listed biotechnology company. In 2010, Novavax was named one of the ten most innovative companies in the biotechnology industry by Fast Company magazine. During his tenure at Novavax, Dr. Singhvi transformed the company from a specialty pharmaceutical business to a premier vaccine development company. Singhvi’s professional career began at Merck & Co in 1994, where he held several key positions in R&D and manufacturing. At Merck, he co-lead the varicella-zoster virus vaccine project team that oversaw the development of Varivax®III (chickenpox vaccine), ProQuad® (MMRV pediatric combination vaccine) and Zostavax® (Shingles vaccine).
Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his MS and ScD chemical engineering degrees from MIT. He received an MBA degree from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.